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Abstract
Gomesin is a potent antimicrobial peptide (AMP) isolated from hemocytes of the spider Acanthoscurria gomesiana.
The present study aimed at determining whether gomesin exerted antitumor activity in vitro and in vivo. Topical
treatment of subcutaneous murine melanoma with gomesin incorporated in a cream base significantly delayed
tumor growth. A direct cytotoxicity of gomesin in murine melanoma B16F10-Nex2 cells and several human tumor
cell lineages was observed in vitro, with IC50 values below 5 μM. The β-hairpin structure of gomesin with disulfide
bridges seemed essential for optimal activity. D-Gomesin was equally active. A membrane-permeabilizing activity
was suggested, as gomesin bound to the cell membrane and cytoplasmic lactate dehydrogenase was detected
extracellularly. At doses causing partial growth of tumor cells, gomesin allowed internalization of macromolecules
(immunoglobulins), which increased the cytotoxic effect. The in vivo antitumor effect of gomesin might also in-
volve a cytotoxic effect on endothelial cells because cultured human endothelial cells were killed in vitro at a similar
concentration range. This effect represents a novel and potential use for gomesin as a topical agent against un-
successfully treated intradermal and epithelial skin cancers. To our knowledge, this is the first report on the suc-
cessful topical use of AMPs in cancer treatment.
Neoplasia (2008) 10, 61–68
Introduction
Cancer chemotherapy has several pitfalls. The majority of drugs is ac-
tive against rapidly proliferating cancer cells, whereas slow-growing tu-
mors or dormant cells respond poorly to these agents [1]. Cancer cells
frequently develop multidrug resistance, which greatly reduces the ar-
senal of chemotherapeutic drugs [2,3]. Antiangiogenic drugs, which
reduce or abrogate the blood supply in solid tumors, are promising
new therapeutic agents [4]. Emerging evidence, however, shows that
tumors can also develop resistance to angiogenesis inhibitors [5].
Antimicrobial peptides (AMPs) are natural-source drugs that show
a potential use as anticancer agents [6]. AMPs, mostly cationic and
amphipathic molecules, are expressed in a variety of species (e.g., in-
sects, fish, amphibians, and mammals) and can directly eliminate a
broad range of Gram-negative and Gram-positive bacteria, fungi, en-
veloped viruses, and protozoa [7]. These molecules are grouped in
different classes according to their structural characteristics [8].
Abbreviations: AMP, antimicrobial peptide; FITC, fluorescein isothiocyanate; Gm,
gomesin; HUVEC, human umbilical vein endothelial cell; LDH, lactate dehydroge-
nase; mAb, monoclonal antibody
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Some AMPs exhibit in vitro direct cytotoxic activity against cancer
cells. Cathelicidins (BMAP-28 and hCAP-18), cecropins, melittin,
magainin 2, defensins, lactoferricin, and tachyplesin were cytotoxic
to human leukemia, lymphoma, breast, lung, ovarian, cervical, and
oral squamous carcinoma cells [6]. Rabbit and human α-defensins
isolated from granulocytes killed human and murine tumor cell lines
in vitro [9]. α-Defensins inhibited angiogenesis [10] and lactoferricin
B killed several murine tumor cells in vitro and showed in vivo activ-
ity [11–13]. It has not been possible, however, to predict an antitu-
mor activity based on the peptide structure.
Gomesin (Gm) is a cationic AMP isolated from hemocytes of the
unchallenged Brazilian spider Acanthoscurria gomesiana [14]. It con-
tains 18 amino acid residues (ZCRRLCYKQRCVTYCRGRNH2)
and carries two posttranslational modifications, the N-terminal pyro-
glutamic acid (Z) and the C-terminal amidated arginine residue. The
hairpin-like two-stranded antiparallel β-sheet structure is maintained
by two internal disulfide bridges formed by four cysteine residues,
Cys2–15 and Cys6–11, which stabilize a rigid conformation together
with six hydrogen bonds in the central part of the molecule as well
as at each end of the β-sheet [15]. The peptide is highly amphipathic,
with a hydrophobic face formed by residues Leu5, Tyr7, Val12, and
Tyr14, and three hydrophilic regions containing positively charged
and polar amino acids located at the N-terminus (Arg3 and Arg4),
at the C-terminus (Arg16 and Arg18), and within the noncanonical
β-turn (Lys8, Gln9, and Arg10) [16].
Gomesin exerts a strong microbicidal activity against Gram-positive
and Gram-negative bacteria, filamentous fungi, yeast and parasites,
such as Leishmania amazonensis, Plasmodium falciparum, and Plasmodium
berghei [14,17].
In the present work, we investigated the direct cytotoxic activity of
Gm on murine and human tumor cells, and examined the possible
in vivo use of this peptide in the treatment of subcutaneous murine
melanoma B16F10-Nex2.
Materials and Methods
Peptide Synthesis
Gomesin and all structural derivatives were synthesized using the
classic solid-phase methodology on a 4-methylbenzhydrylamine-resin
[15]. Structures and molecular weights of all peptides are depicted
on Table 1.
Tumor Cell Lines and Cell Culture
The murine melanoma cell line B16F10 was originally obtained
from the Ludwig Institute for Cancer Research (São Paulo, Brazil).
The melanotic B16F10-Nex2 subline, isolated at the Experimental On-
cology Unit, is characterized by low immunogenicity and moderate
virulence. Human breast adenocarcinoma (SKBr3), colon adenocarci-
noma (LS180), and cervical cancer (HeLa) cell lines were obtained
from the Ludwig Institute for Cancer Research. Human melanoma cell
lines (SKMel 19 and A2058) were provided by Dr. Alan N. Houghton
of Memorial Sloan Kettering Cancer Center, NY. All cells were cultured
at 37°C in a humidified atmosphere containing 5% CO2, in RPMI-
1640 medium (Invitrogen, Carlsbad, CA) supplemented with 10 mM
N-2-hydroxyethylpiperazine-N2 ethanesulfonic acid (Hepes) (Sigma,
St. Louis, MO), 24 mM sodium bicarbonate (Sigma), 40 mg/l genta-
mycin (Schering-Plough, São Paulo, Brazil), pH 7.2, and 10% fetal calf
serum (Invitrogen).
Antibodies
Murine anti–α-tubulin (IgG, clone DM1A) was from Sigma. Murine
anti–pan-histones antibodies were from Boehringer Mannheim (Ger-
many). Anti-Gm is a polyclonal rabbit antibody [18]. Monoclonal anti-
body (mAb) A4M is a histone H1–reacting IgM raised against
B16F10-Nex2 melanoma cells.
B16F10-Nex2 Nuclear Extract and Chemiluminescent
Immunoblot Analysis with mAb A4M
Approximately 200 μl of cell pellet (5 × 107 B16F10-Nex2 cells)
was diluted in five volumes of buffer A (10 mM Hepes, 1.5 mM
MgCl2, 10 mM KCl, and 0.5 mM DTT) and incubated on ice
for 10 minutes. After centrifugation, the original pellet was resus-
pended in two volumes of buffer A. Tumor cells were lysed in a Pot-
ter homogenizer and centrifuged for 20 minutes at 25,000g. The
pellet was resuspended in 3 ml of buffer B [20 mM Hepes, 25%
(v/v) glycerol, 0.42 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA,
0.5 mM PMSF, and 0.5 mM DTT] and was homogenized again.
The suspension was softly agitated 30 minutes on ice and centrifuged
for 30 minutes at 25,000g. The supernatant was dialysed in 50 vol-
umes of buffer C [20 mM Hepes, 20% (v/v) glycerol, 0.1 M KCl,
0.2 mM EDTA, 0.5 mM PMSF, and 0.5 mM DTT] for 12 hours at
4°C. After centrifugation for 20 minutes at 25,000g, the supernatant
was collected and used for immunoblot analysis with mAb A4M. Pu-
rified commercial H1 histone from calf thymus (Type III SS; Sigma)
was used as control. Melanoma nuclear extract and commercial
histones were eletrophoretically separated in 15% sodium dodecyl
sulfate–polyacrylamide gel electrophoresis, and transferred to a nitro-
cellulose membrane. After blocking, membranes were incubated with
mAb A4M or murine anti–pan-histone antibody (Boehringer Mann-
heim) for 12 hours at 4°C under agitation, following incubation
with biotinylated total murine anti-IgG or anti-IgM (Sigma) and
streptavidin–peroxidase (Sigma), at 37°C, for 1 hour each. Mem-
branes were revealed with enhanced chemiluminescence (Amersham
GE, São Paulo, Brazil).
In Vitro Cytotoxic Activity
Gomesin and derivatives were diluted in supplemented RPMI
medium and incubated with 5 × 103 B16F10-Nex2 or 104 human
tumor cells in 96-well plates; cells were plated 24 hours before
Table 1. Primary Structures and Molecular Mass of Gm and Derived Peptides.
Peptide Sequence Molecular Mass
Gomesin (Gm) 2270.7
D-Gomesin (D-Gm) 2270.7
[Ser2,6,11,15]-Gm ZSRRLSYKQRSVTYSRGR-NH2 2210.5
[Ser2,15]-Gm 2240.6
[Ser5]-Gm 2244.6
[Ser12]-Gm 2258.7
[Ser5,12]-Gm 2232.6
Underlined peptides: Cysteine-to-serine substitutions.
Bold lowercase letters correspond to D-amino acids.
Bold serine units: Serine substitutions of originally hydrophobic residues.
Disulfide bonds are represented by continuous lines connecting cysteine residues.
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treatment. After incubation, viable cells were counted in a Neubauer
chamber (Electron Microscopy Sciences, Hatfield, PA) using Trypan
blue. To analyze the combined effect of Gm and antibodies, B16F10-
Nex2 cells were treated with 2 μM Gm and mAb A4M. Cell viability
was measured after 12 hours of incubation. Human umbilical vein en-
dothelial cells (HUVECs), 104 cells plated as described, were treated
with Gm and cell viability was then analyzed after 16 hours. All experi-
ments were performed in triplicate.
Flow Cytometry
B16F10-Nex2 cells (106 cells/100 μl) were incubated for 12 hours
with 2 μM Gm and 100 μg/ml mAb A4M. As positive permeabiliza-
tion control, cells were treated with 0.5% saponin and 1% para-
formaldehyde in phosphate-buffered saline (PBS), pH 7.2, for
20 minutes, and with mAbs for 12 hours, diluted in the same solution.
Cells were incubated sequentially for 1 hour with biotin-conjugated
murine anti-IgM (Sigma) at 20 μg/ml and streptavidin–fluorescein
isothiocyanate (FITC) (Pharmigen BD Biosciences, San Jose, CA)
at 10 μg/ml, both diluted in PBS, protected from light. All steps
were performed at 4°C, preceded by washings with PBS. Cells were
fixed with PBS–formaldehyde 2% (Merck S.A., São Paulo, Brazil)
in a final volume of 500 μl. The reaction was analyzed in a FACS-
Calibur equipment (Becton-Dickinson, Franklin Lakes, NJ), using
CellQuest software.
Analysis of Morphologic Alterations by Light Microscopy
B16F10-Nex2 cells (104 cells/1 ml) were cultivated in 24-well
plates for 24 hours and incubated for 2 hours with 15 μM Gm or
with 2 μM Gm associated with 100 μg/ml mAb A4M. Cell mor-
phology was monitored every 5 minutes using a microscope (model
IX70; Olympus, Center Valley, PA) at a magnification of ×40.
Images were analyzed using a software (MetaMorph; Molecular De-
vices Co., Sunnyvale, CA).
Lactate Dehydrogenase Assay
B16F10-Nex2 melanoma cells (105) were incubated in 24-well
plates with Gm, in RPMI without serum. Supernatants (100 μl) were
then collected and assayed for the presence of released lactate dehy-
drogenase (LDH) after adding 120 μl of PBS containing 0.7 mM
NADH and 4.7 mM pyruvate. The decrease in A340 after 1 minute
of incubation was measured. The initial A340 of NADH added was
taken as 100% or 1. Lower values indicated consumptions relative to
100%. Positive control consisted of a Triton X-100 (10%) B16F10-
Nex2 cell lysate. All experiments were performed in triplicate.
Confocal Microscopy
B16F10-Nex2 cells (2 × 103) were cultivated in round glass cover-
slips (13 mm) for 24 hours [19], following incubation with 5 μM
Gm for 10 minutes at 37°C, and fixation with 3.7% paraformaldehyde
for 15 minutes at room temperature. Cells were then incubated in
150 mM NaCl (Merck), 50 mM Tris (Gibco Invitrogen, Carlsbad,
CA), 0.25% BSA (Sigma), and 0.5% Tween 20 (Sigma), pH 7.2 to
7.4, for 1 hour at room temperature, with mouse antibodies against
α-tubulin (1:100 ascite dilution) for 12 hours at 4°C, and finally with
4 μg/ml FITC-conjugated goat anti-mouse antibody (Molecular Probes
Invitrogen, Carlsbad, CA). Alternatively, cells were incubated with rab-
bit polyclonal anti-Gm antibodies, 1:200 diluted, and revealed with
FITC-conjugated goat anti-rabbit antibody (5 μg/ml) (ICN Biochemi-
cals Inc., Irvine, CA). Staining of actin filaments and nuclei were per-
formed with 0.3 μg/ml phalloidin–rhodamine conjugate (Invitrogen)
and 50 μg/ml DAPI (Invitrogen), respectively, for 1 hour at room tem-
perature. The coverslips were mounted using a mounting medium
(Vectashield; Vector Laboratories, Burlingame, CA) to reduce bleaching
and were examined by a laser scanning fluorescence confocal micro-
scope (MRC 1024/UV System; Bio-Rad, Hercules, CA) equipped with
a transmitted light detector for Nomarski differential interference con-
trast. The images were obtained with a 40× 1.2 NA/water immersion
PlanApo objective (Carl Zeiss MicroImaging, Inc., Thornwood, NY);
Kalman averaging at least 20 frames using a 2-mm iris (pinhole) [20].
Extracellular Acidification Rate
B16F10-Nex2 cells (3 × 105 cells/ml) were added into 3.0-μm-pore
cups (Transwells; Corning Costar, Cambridge, MA) held on 12-well
plates 12 hours before the experiment. The extracellular acidification
rate of treated and untreated cells was determined using a bioassay
(Cytosensor Microphysiometer; Molecular Devices, Sunny Valley,
CA). The capsules containing the adherent cells were allowed to equili-
brate in low buffered RPMI containing 1% BSA for 20 minutes at
37°C, when the acidification rates were normalized to 100% before
drug addition. Cells were perfused for 400 minutes with 200 μM cis-
platin or 10 μM Gm. During the flow-off periods, protons released
from the drug-treated cells accumulated in the sensor chamber, and
the H+ decay profile was quantified [21].
Topical Treatment of Subcutaneous Murine Melanoma
Seven- to eight-week-old male C57BL/6 mice from Centro de
Desenvolvimento de Modelos Experimentais, UNIFESP (average
weight of 32–34 g each), had the right flank chemically depilated
with a hair removal cream (Veet; Reckitt Benckiser, São Paulo, Brazil)
and, 24 hours later were injected subcutaneously with 105 B16F10-
Nex2 tumor cells. Gomesin (200 μg/100 μl water) was incorporated
in 1 g of anionic, oil-in-water cream (final concentration, 0.02% w/w
of Gm). Topical treatment started when subcutaneous tumor volumes
reached 4 to 10 mm3 and consisted of spreading 20 mg of cream with
a small brush over the tumor external surface, three times a week for
4 weeks or until the tumor volume reached a maximum of 3000 to
3300 mm3, and then the animals were sacrificed. The maximum tu-
mor size accepted was calculated based on the weight of the male mice
used, i.e., 32 to 34 g. The control group was treated with a water-
incorporated cream. Tumor volumes were measured three times a
week, before treatment, using the formula V = 0.52 ×D1
2 ×D2, where
D1 and D2 are short and long tumor diameters, respectively. Ani-
mal manipulation was conducted according with the guidelines of
the Animal Ethics Committee of Federal University of São Paulo
(UNIFESP), protocol no. 316/06.
Statistical Analysis
Two-tailed Student’s t test was used for statistical analysis of in vitro
experiments. In the case of data presentation using percent values (as in
Figure 2), the original numbers were used for statistic comparison with
the control. The plots of treated living animals below the maximum
allowed tumor size were analyzed statistically by the log rank test com-
pared with the control group. The IC50 value and 95% confidence
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intervals were calculated using GraphPad InStat3 software (GraphPad
Software Inc., San Diego, CA).
Results
Local Treatment with a Gomesin-Containing Cream
Significantly Increased the Survival Time of
B16F10-Nex2–Challenged Mice with Tumors
Showing Delayed Growth
Animals with established subcutaneous tumors (4–10 mm3) were
treated topically three times a week, with individual doses of 4 μg
of Gm in 20 mg of cream. Strikingly, a significant delay in tumor
development was observed in treated animals (Figure 1A). Treated
animals also had significantly increased survival times as compared
with controls, with mice being sacrificed when tumors reached the
maximum size (3000 mm3) allowed (P < .01; Figure 1B).
Gomesin Reduced Viability of Murine and Human Tumor
Cell Lines, and also of a Human Endothelial Cell Lineage
(HUVEC) In Vitro, but Showed Reduced Cytotoxic at
Erythrocytes and Macrophages
The antitumor local effect of gomesin in vivo could be due to
Gm direct cytotoxicity in tumor cells. In vitro, after 12 hours of
incubation with 20 μM Gm, B16F10-Nex2 melanoma cells lost
Figure 1. Topical treatment with a gomesin-containing cream de-
layed subcutaneous tumor development and increased the time of
living animals with tumors below the maximum allowed size.
B16F10-Nex2 murine melanoma cells (105 per animal) were in-
jected subcutaneously into the hair-free flank of C57BL/6 male
mice. Animals were treated topically with a Gm-containing cream
(white circles, n = 10) or a control cream (black circles, n = 5), as
described in Materials and Methods. (A) Individual tumor volumes.
(B) Treated and control mice bearing tumors bellow 3000 mm3
after different times of tumor implantation. Log rank test, P < .01.
Figure 2. The antimicrobial peptide gomesin showed in vitro cyto-
toxic effect on B16F10-Nex2 murine tumor cells, in a dose-, time-,
and structure-dependent fashion. (A) Tumor cells were incubated
for 12 hours with 20 μM gomesin (Gm), its D-enantiomer (D-Gm),
monocyclic {[Ser2,15]-Gm}, linear {[Ser2,6,11,15]-Gm}, forms, and
with 10 μM analogues with amino acid substitutions disrupting
the hydrophobic face of the peptide, [Ser5]-Gm, [Ser12]-Gm, and
[Ser5,12]-Gm. (B) Cells were incubated with different concentra-
tions of Gm (1, 5, 10, and 20 μM) for 15 minutes up to 5 hours.
Cells were alternatively incubated with Gm for 5 hours, washed
to eliminate the peptide, and incubated with fresh medium for
24 hours (5/24 h). Cell viability was determined by counting cells
in presence of Trypan blue. Data are a representative experiment
of a triplicate set. Bars represent means and standard deviations
(SD). *P < .05 and #P < .01 relative to the control.
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viability (Figure 2A). The IC50 value for these tumor cells was 3.58 μM
(Table 2). The enantiomer D-gomesin (D-Gm), which was synthesized
employing D-amino acids and containing both disulfide bonds, was also
highly cytotoxic implying that chiral recognition is not required for
antitumor activity. In contrast, derivatives where cysteine residues had
been substituted by serine, resulting in molecules with one (monocyclic
[Ser2,15]-Gm) or none (linear [Ser2,6,11,15]-Gm) disulfide bond showed
a much reduced tumor cell cytotoxicity, 70% and 30%, respectively
(Figure 2A).
Disruption of the hydrophobic face (amino acid residues Leu5,
Tyr7, Val12, and Tyr14) by serine substitution of Leu5, Val12, or both
residues, completely abolished Gm cytotoxicity (Figure 2A). Substi-
tution of a single hydrophobic residue was sufficient to completely
abrogate peptide activity.
The cytotoxic effect of Gm was time- and dose-dependent (Fig-
ure 2B) and was not reversed by washing, as cells incubated with
Gm (10 and 20 μM) for 5 hours, and subsequently with complete me-
dium in the absence of the peptide did not resume growth (Figure 2B).
Gomesin was also cytotoxic to human tumor cell lineages in vitro,
the most sensitive being human melanoma A2058, with IC50 value
of 1.36 μM. A human endothelial cell lineage (i.e., HUVEC) was
also sensitive in vitro to Gm, with IC50 value of 5.3 μM (Table 2).
Gomesin Bound to and Permeabilized Tumor
Cell Membrane
Anti-Gm rabbit antibody staining showed that Gm accumulates very
rapidly on the tumor cell membrane, forming clusters (Figure 3B). A
preimmune rabbit serum did not react with Gm-treated tumor cells
(data not shown).
Dose-dependent permeabilization of Gm-treated B16F10-Nex2 cells
was shown by the extracellular release of cytoplasmic LDH (Figure 4).
Membrane-permeabilized tumor cells internalized IgMs and the fluo-
rescent staining of tubulin by anti–α-tubulin was possible only after
Gm treatment (Figure 3C ). An irrelevant IgG2a, used as an isotype
control antibody, did not stain the tumor cell (data not shown).
A mAb noncytotoxic to whole melanoma cells was then tested
against Gm-treated B16F10-Nex2 cells in vitro. MAb A4M, recog-
nizing nuclear histone H1 (Figure 5A), was internalized in B16F10-
Nex2 cells (Figure 5B) and showed additive cytotoxic activity with
Gm in vitro (Figure 5C ).
Gm-treated B16F10-Nex2 cells showed early morphologic altera-
tions. Treatment with 15 μM Gm for 15 minutes increased the gran-
ularity in 30% of the cell population and, after 30 minutes, 80% of
cells were heavily granulated and shrunk (Figure 6D). No detach-
ment from the substrate was observed. The additive effect of Gm
and mAb A4M was detected with 2 μg of Gm, 5 minutes after co-
incubation with both reagents. This low dose of Gm alone did not
affect cell morphology even after 120 minutes (Figure 6B). Round
cells were observed suggesting detachment from the extracellular ma-
trix and, after 10 minutes, 100% of the cell population assumed
round forms (Figure 6E ) and had increased cytoplasmic granularity
after 15 minutes (Figure F ).
Table 2. Estimated IC50 and 95% Confidence Intervals (CIs) of Gomesin Cytotoxic Effect in
Murine and Human Cell Lines.
Tumor and Endothelial Cells IC50 (95% CI), μM
B16F10-Nex2 3.58 (2.76–4.41)
SKBr3 2.87 (1.30–4.45)
LS180 4.78 (2.82–6.75)
A2058 1.36 (0.29–3.02)
HeLa 8.13 (6.00–10.25)
SKMel 19 2.35 (1.69–3.00)
HUVEC 5.30 (2.21–8.46)
Figure 3. Gomesin accumulated on the cell membrane and per-
meabilized B16F10-Nex2 tumor cells. Cells were cultivated on
round glass coverslips, treated with 5 μM Gm for 10 minutes,
fixed, and incubated with anti–Gm polyclonal monospecific anti-
body (B), or murine antitubulin antibody (C), both revealed with
FITC-conjugated secondary antibodies (green). The fluorescence
was analyzed by confocal microscopy as described in Materials
and Methods. Red, phalloidin–rhodamine; blue, DAPI staining. (A)
Single optical section through control cells treated with phalloidin–
rhodamine, DAPI, and antitubulin in the absence of Gm; (B, C)
maximum pixel value projections of serial optical sections. Scale
bars, 20 μm.
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Early Effects of Gomesin on Tumor Cell
Respiratory Metabolism
The extracellular acidification rate was measured after B16F10-Nex2
cell treatment with Gm and cisplatin, a control apoptotic drug. Using
Cytosensor Microphysiometer, cisplatin at 200 μM slowly reduced the
external proton concentration, reaching values 85% lower than the base-
line values only after 400 minutes of incubation (Figure 7). Gomesin
(10 μM) caused 40% reduction in the extracellular acidification rate
after 200 minutes of incubation, keeping it steady until 400 minutes.
Discussion
Although numerous AMPs have been discovered in the last years,
only a few were tested as in vivo drugs against tumor cells [6].
Human melanoma subcutaneously injected in nude mice was treated
with local injections of D-magainin [22] and lactoferricin B–inhibited
neuroblastoma xenografts [13].
Antimicrobial peptides have been successfully used for treatment
of superficial infections, as topical drugs. In thermally injured and
Pseudomonas aeruginosa–infected rat skin, protegrin decreased bac-
terial counts after topical application or intradermal injection [23].
Topical treatment of melanoma is, sometimes, a preferred alterna-
tive. Some patients develop extensive, confluent cutaneous metastases
near the primary nodular melanoma, and these lesions are unsuitable
for surgical excision or radiotherapy. Some topical treatments have ten-
tatively being used, but only partial responses were obtained with
5-aminolevulinic acid photodynamic therapy [24], imiquimod [25,26],
dinitrochlorobenzene [27–29], and diphencyprone [30].
Our results show that topical treatment with Gm, an AMP struc-
turally related to androctonin and protegrin [14,15], significantly de-
layed subcutaneous murine melanoma development and increased
the number of living treated animals with tumors below the allowed
maximal size limit. Apparently, the antitumor activity of gomesin was
due to a direct effect on tumor cells. Gomesin was cytotoxic in vitro
to murine and human tumor cells (melanoma, breast, and colon car-
cinoma) at doses lower than 5 μM, except for human HeLa cells,
which showed an IC50 value of 8.13 μM.
Gomesin was also cytotoxic to HUVECs in vitro with IC50 in the
same range as for tumor cells, suggesting that in vivo both tumor
Figure 4. Gomesin treatment of B16F10-Nex2 cells in vitro induced
leakage of cytoplasmic LDH. Cells were incubated with 5, 10, or
20 μM Gm for 5, 15, and 30 minutes, and the activity of LDH in
the culture supernatants was quantified by NADH consumption,
as described in Materials and Methods. Control, untreated cells;
Triton, cells treated with 10% of Triton X-100 for maximal lysis
of tumor cells. Data are a representative experiment of a tripli-
cate set. Bars represent means and SD. *P < .01 compared to re-
spective control.
Figure 5. Immunoglobulins (IgM) were detected in the cytoplasm
of B16F10-Nex2 murine melanoma cells permeabilized with a low
dose of gomesin. (A) Chemiluminescent immunoblot analysis
showing mAb A4M reactivity with histone 1. NE B16, nuclear ex-
tract of B16F10-Nex2 cells; H1 Sigma, commercially purified calf
thymus histone from Sigma. Lane 1, 25 μg/ml mAb A4M; Lane 2,
25 μg/ml commercial anti–pan histone antibody; Lane 3, 25 μg/ml
an irrelevant mAb. (B) Cells were incubated with a low dose of Gm
(2 μM) or with 0.5% saponin and 100 μg/ml mAb A4M for 12 hours.
Samples were incubated with FITC-conjugated secondary antibo-
dies and cytoplasmic fluorescence was quantified by FACS. None,
untreated cells; Ig-FITC, cells treated with secondary antibodies in
the absence of mAbs; FL1-H, fluorescence intensity. (C) Cells
were incubated with different concentrations of A4M mAb (25,
50, 80, and 100 μg/ml) in presence (+Gm) or absence (−Gm) of
2 μM Gm for 12 hours. Viable cells were counted in the presence
of Trypan blue. None, untreated cells; Gomesin, cells treated with
2 μM Gm. Data are a representative experiment of a triplicate set.
Bars represent means and SD.
66 Topical Treatment of Melanoma With Gomesin Rodrigues et al. Neoplasia Vol. 10, No. 1, 2008
and endothelial cells of the microvascular core might be affected by
the peptide.
Repeated topical applications of Gm did not affect the peripheral
healthy skin of peptide-treated mice. Silva et al. [14] previously have
shown a minimal hemolytic activity of gomesin in vitro, and we also
observed the complete absence of cytotoxicity of the peptide in thio-
glycollate-elicited peritoneal murine macrophages in vitro (data not
shown). Gomesin did not stimulate the production of nitric oxide
in these macrophages, thus differing from human β-defensin 2
[31]. Seemingly normal cells may be resistant to gomesin unlike tumor
cells and cultured endothelial cells.
Gm tumor cell cytotoxicity depended on the β-hairpin configura-
tion with at least one disulfide bridge for keeping a significant activ-
ity, whereas both bridges are required for high serum stability and
optimal activity [16,32]. Apparently, in AMPs with β-hairpin struc-
ture, amphiphilicity, charge, and shape are more important to anti-
microbial activity than the presence of specific amino acids [33].
Electrostatic and hydrophobic interactions are important for the anti-
microbial activity of Gm [32,34,35]. Gomesin apparently did not re-
quire a specific surface receptor to reduce tumor cell viability, because
D-Gm was as cytotoxic as the native peptide. The same independence
of chirality was observed for the antimicrobial effect of Gm [14] and
protegrin [33].
Treatment of tumor cells with Gm did not induce apoptosis. After
12 hours of incubation, cellular DNA was not degraded (data not
shown). In a dose-dependent manner, gomesin induced morpho-
logic cell alterations with increased granularity, loss of cytoplasmic
content by membrane permeabilization, and partial collapse of the
proton gradient.
Gm at low concentrations could facilitate the penetration of drugs
inside tumor cells, thus potentially reducing toxic doses. Other-
wise, Gm could allow molecules that are not directly cytotoxic to
cells with intact membranes, act to eliminate these cells after pep-
tide treatment.
There is no data up to now concerning the precise mode of action
of Gm; however, the high structural similarities with protegrin [15]
suggest that a similar mode of action through formation of pores may
also occur [15,36]. As the peptide concentrates at the cell membrane,
clusters can be seen suggesting the formation of pore structures.
The putative pore formation by Gm caused the release of LDH
from melanoma cells and inhibited the respiration-dependent proton
gradient in treated cells. After Gm treatment, tubulin filaments were
stained by specific IgG, and this effect did not occur in the absence of
the peptide. Moreover, treatment of tumor cells with a low dose of
Gm allowed internalization of mAb A4M that reacted with histone
H1. The enhanced cytotoxicity observed by the association of Gm
and mAb A4M was observed at relatively high concentrations of
the antibody (80–100 μg/ml).
Most importantly, our results describe a novel and important use
for Gm as a topical drug against intradermal and intraepithelial can-
cers. To our knowledge, this is the first report describing the success-
ful topical use of AMPs in cancer treatment.
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